| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Simon Haroutounian | Q56435682 |
| Shimon Lecht | Q74608856 | ||
| P2093 | author name string | Amnon Hoffman | |
| Elyad Davidson | |||
| Arik A Zur | |||
| P2860 | cites work | Myasthenia gravis presenting as weakness after magnesium administration | Q28335813 |
| Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab | Q30320119 | ||
| Etoricoxib: a highly selective COX-2 inhibitor | Q33213983 | ||
| Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study | Q33628003 | ||
| Clinical pharmacokinetics of mexiletine | Q33789223 | ||
| Pharmacotherapy of trigeminal neuralgia | Q34110447 | ||
| The new generation of GABA enhancers. Potential in the treatment of epilepsy | Q34320951 | ||
| Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs | Q34326331 | ||
| ABC multidrug transporters: structure, function and role in chemoresistance. | Q34586418 | ||
| An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy | Q34590272 | ||
| The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective | Q35129048 | ||
| Current applications of plasmapheresis in clinical toxicology | Q35158457 | ||
| Update on myasthenia gravis | Q35520740 | ||
| Pathophysiology of myasthenia gravis | Q35824189 | ||
| Anesthesia issues in the perioperative management of myasthenia gravis | Q35824219 | ||
| Myasthenia gravis: clinical, immunological, and therapeutic advances | Q36006116 | ||
| Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis | Q36254764 | ||
| Mycophenolate mofetil treatment of myasthenia gravis | Q36364969 | ||
| Adverse drug effects on neuromuscular transmission | Q37879503 | ||
| Pharmacokinetic drug interactions with cyclosporin (Part I). | Q37956836 | ||
| Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid | Q38367145 | ||
| Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study | Q39388670 | ||
| Remission of myasthenia gravis following plasma-exchange | Q39413756 | ||
| Intravenous magnesium sulfate rapidly alleviates headaches of various types | Q39466774 | ||
| Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy | Q39501933 | ||
| Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain | Q39538201 | ||
| Buprenorphine kinetics | Q39570069 | ||
| Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease | Q40261410 | ||
| Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. | Q40480676 | ||
| Chronic post-sternotomy pain | Q40684344 | ||
| Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters | Q40809978 | ||
| Comparative pharmacokinetics of the newer antiepileptic drugs | Q40918364 | ||
| Postherpetic neuralgia--pathogenesis, treatment, and prevention | Q40990582 | ||
| The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine | Q41128202 | ||
| Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers | Q42595309 | ||
| Pharmacokinetics of the anticonvulsant drug clonazepam evaluated from single oral and intravenous doses and by repeated oral administration | Q42597665 | ||
| The pharmacokinetics of baclofen derived from intestinal infusion | Q42663367 | ||
| Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). | Q43515162 | ||
| Carbamazepine poisoning: treatment with plasma exchange | Q43630472 | ||
| Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs | Q44443132 | ||
| Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin | Q44509555 | ||
| Acute renal failure and oligohydramnios induced by magnesium dypirone (metamizol) in a pregnant woman | Q44535847 | ||
| Antibody positive myasthenia gravis following treatment with carbamazepine--a chance association? | Q44642507 | ||
| Carbamazepine and myasthenia gravis | Q45029937 | ||
| Etanercept treatment in corticosteroid-dependent myasthenia gravis | Q45205192 | ||
| Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833. | Q46411656 | ||
| Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis | Q46481573 | ||
| Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children | Q46562473 | ||
| Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier | Q46668112 | ||
| Effect of plasma exchange on carbamazepine levels in a patient with myasthenia gravis and epilepsy | Q46815990 | ||
| Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. | Q47939695 | ||
| P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier | Q48238618 | ||
| Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis | Q48572059 | ||
| Undiagnosed myasthenia gravis masquerading as eclampsia | Q48574854 | ||
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 | ||
| Intravenous magnesium sulphate decreases postoperative tramadol requirement after radical prostatectomy | Q48682829 | ||
| Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). | Q48705632 | ||
| Immunoglobulin treatment in refractory Myasthenia gravis. | Q53915737 | ||
| P433 | issue | 3 | |
| P921 | main subject | myasthenia gravis | Q8285 |
| pain management | Q621261 | ||
| P304 | page(s) | 242-260 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Journal of Pain and Palliative Care Pharmacotherapy | Q6295706 |
| P1476 | title | The challenge of pain management in patients with myasthenia gravis | |
| P478 | volume | 23 |
Search more.